Icosapent

Generic Name
Icosapent
Brand Names
Animi-3 With Vitamin D
Drug Type
Small Molecule
Chemical Formula
C20H30O2
CAS Number
10417-94-4
Unique Ingredient Identifier
AAN7QOV9EA
Background

Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conversion into the thromboxane-2 and prostaglandin-2 families.

Indication

EPA can be used for lowering elevated triglycerides in those who are hyperglyceridemic. In addition, EPA may play a therapeutic role in patients with cystic fibrosis by reducing disease severity and may play a similar role in type 2 diabetics in slowing the progression of diabetic nephropathy.

Associated Conditions
-
Associated Therapies
Dietary and Nutritional Therapies
Clinical Trials
Related News

Differential Thrombogenesis by EPA and DHA Mediated by HDL

Early Phase 1
Not yet recruiting
Conditions
Lipid Metabolism Disorders
Interventions
Drug: DHA
Drug: EPA
First Posted Date
2024-07-10
Last Posted Date
2024-12-17
Lead Sponsor
The Miriam Hospital
Target Recruit Count
80
Registration Number
NCT06494488

Long-term Safety and Efficacy Study of MND-2119 in Patients With Hypertriglyceridemia

Phase 3
Completed
Conditions
Hypertriglyceridemia
Interventions
Drug: Icosapent
First Posted Date
2020-01-09
Last Posted Date
2021-08-23
Lead Sponsor
Mochida Pharmaceutical Company, Ltd.
Target Recruit Count
120
Registration Number
NCT04221217
Locations
🇯🇵

Mochida Investigational sites, Tokyo, Japan

Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

First Posted Date
2019-07-05
Last Posted Date
2022-07-01
Lead Sponsor
Milton S. Hershey Medical Center
Target Recruit Count
1
Registration Number
NCT04006847
Locations
🇺🇸

Penn State Cancer Institute, Hershey, Pennsylvania, United States

A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia

Not Applicable
Completed
Conditions
Cancer Cachexia
Interventions
Drug: Eicosapentaenoic Acid
First Posted Date
2008-12-30
Last Posted Date
2017-03-23
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
36
Registration Number
NCT00815685
Locations
🇺🇸

Martin Memorial, Stuart, Florida, United States

🇺🇸

H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia

Phase 4
Completed
Conditions
Dyskinesia
Schizophrenia
First Posted Date
2005-06-16
Last Posted Date
2005-06-24
Lead Sponsor
University of Stellenbosch
Target Recruit Count
84
Registration Number
NCT00114595
Locations
🇿🇦

Department of Psychiatry, Department of Health sciences, University of Stellenbosch, Cape Town, Western Cape, South Africa

Effect of Polyunsaturated Fatty Acids on Cardiovascular and Motor Responses Under Stress

Phase 1
Completed
Conditions
Healthy
First Posted Date
2001-04-09
Last Posted Date
2017-07-02
Lead Sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Target Recruit Count
97
Registration Number
NCT00014027
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy